Tacrolimus: Effectiveness, Safety and Drug Interactions

Dimitrios Raptis, PhD (Editor)
Surgical Department, University of Erlangen-Nuremberg, Erlangen, Germany

Manousos-Georgios Pramateftakis (Editor)
Aristotle University of Thessaloniki, Gen. Hospital ”G. Papanikolaou”, Thessaloniki, Greece

Series: Pharmacology – Research, Safety Testing and Regulation, Immunology and Immune System Disorders
BISAC: MED071000

Clear

$179.00

Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

Since its discovery in 1984, Tacrolimus has proven itself to be an invaluable tool in the armamentarium of immunosuppression after organ transplantations. Tacrolimus was first introduced as a rescue therapy in liver transplant patients and quickly showed promise in its ability to improve patient and graft survival, while nowadays there is data demonstrating its effectiveness as a monotherapy immunosuppressive regimen after liver transplantation.

Moreover, Tacrolimus shows promising results in the fields of regenerative response after transplantation, dermatology, multiple autoimmune diseases, healing of colonic anastomoses, platelet activity and thrombotic disorders, and Hereditary Hemorrhagic Telangiectasia (HHT). This hardcover edition comprehensively discusses different issues and aspects concerning the multimodal effects and the safety of this widely used, relatively new, immunosupressant and could be considered an optimal tool for every clinician, since the action of Tacrolimus is no longer limited to post-transplant patients, but also extends to its usage in multiple medical fields. (Imprint: Nova Biomedical )

Preface

Chapter 1: Tacrolimus Properties and Formulations: Potential Impact of Product Quality on Safety and Efficacy
(Ziyaur Rahman, Ahmed Zidan and Mansoor A. Khan, Division of Product Quality and Research, Center of Drug Evaluation and Research, Food and Drug Administration, MD, USA, and others)

Chapter 2: Tacrolimus: A Clinician's Perspective on What is Important
(Preeti Singhai and Jeremy Chapman, Centre for Transplant and Renal Research, University of Sydney, Westmead Hospital, Westmead, Australia)

Chapter 3: Pharmacogenetics of Tacrolimus in Solid Organ Transplantation: One More Approach to Manage its Effectiveness and Safety
(María José Herrero, Virginia Bosó, Jesús Ruiz, Luis Rojas, Sergio Bea, Jaime Sánchez Plumed, Julio Hernández, José Luis Poveda and Salvador F. Aliño, Pharmacogenetics Unit, Service of Pharmacy and IIS La Fe, Politechnic University Hospital La Fe, Valencia, Spain, and others)

Chapter 4: Tacrolimus: A Review of its Efficacy and Potential as Monotherapy in Liver Transplantation
(Ebube Bakosi, Emily Bakosi and Henkie Tan, The Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA, and others)

Chapter 5: Tacrolimus and Liver and Kidney Regeneration
(D. Kahn, Department of Surgery, University of Cape Town, South Africa)

Chapter 6: Topical Tacrolimus: Efficacy and Tolerability
(Frederick J. Lee and Constance H. Katelaris, Clinical Research Program, St. Vincent’s Centre for Applied Medical Research, Sydney, Australia, and others)

Chapter 7: Influence of Tacrolimus on the Healing of Colonic Anastomoses in Rats under Artificially Obstructive Conditions
(D. Raptis, M.G. Pramateftakis, I. Mantzoros, D. Kanellos and I. Kanellos, Surgical Department, Friedrich-Alexander University of Erlangen-Nuremberg, Germany, and others)

Chapter 8: Effect of Tacrolimus on Thrombotic-Related Mechanisms
(José J. Zamorano-León, Antonio J. López-Farré, Javier Modrego Martín, Pablo Rodríguez-Sierra and Alberto Barrientos Guzmán, Cardiovascular Research Unit of Cardiology and Nephrology Departments, Hospital Clínico San Carlos de Madrid, Spain)

Chapter 9: Tacrolimus as a Therapeutic Drug in Hereditary Hemorrhagic Telangiectasia (HHT)
(V. Albiñana, L. Velasco, R. Zarrabeitia and L.M. Botella, Center for Biological Investigations (CIB), Spanish Research Council, Madrid, Spain, and others)

Index

You have not viewed any product yet.